: iStockAnalyst.com Symbols Feed

Options Intelligence Report: High Energy Rewards For Option Trader At RRI

Tue, 03 Nov 2009 18:20:31 GMT

Today's tickers: RRI, WFR, CAR, FRX, SWK, BNI & WFR[More...]

Forest's COPD Drug Disappoints

Thu, 20 Aug 2009 00:29:50 GMT

Yesterday, Forest Laboratories (FRX) announced disappointing results from the mid-stage clinical trials of oglemilast, meant for chronic obstructive pulmonary disease (COPD) that usually affects smokers. The drug was being developed with Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned unit of India-based Glenmark Pharmaceuticals. The phase IIb trial was conducted to determine the proper dosage for the drug. The 12-week trial was conducted on 428 patients aged 40 years or more and who had been smokers for about ten years. Oglemilast failed to show any improvement compared to a placebo during the study which evaluated a once-daily dosage of the drug in three dosage strengths (200 mcg, 400 mcg and 800 mcg). All 428 patients were randomized to receive one of the three doses of oglemilast (n=320) or placebo (n=108) and were[More...]

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

The Long And The Short Of It All: Fair Value By The Market

Thu, 16 Jul 2009 14:40:32 GMT

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet. Cisco Systems (CSCO: 19.57, +0.84 (+4.48%)) Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. [More...]

Analyst Blog: Forest Labs (NYSE: FRX) Pipeline Crucial

Thu, 18 Jun 2009 15:18:00 GMT

Forest Laboratories, Inc.'s (NYSE: FRX) financial results for 2009 were inline with our expectations. EPS fell 3% on revenue growth of 2% as operating cost growth outpaced that of revenue.[More...]

S&P 500 Stocks

Sun, 05 Apr 2009 01:35:00 GMT

The S&P 500 comprises of 500 large cap common stocks actively traded in the United States. The largees public companies that are traded on the New York Stock Exchange (NYSE) and NASDAQ are included in the S&P 500 index. The S&P 500 index was lunched in 1957 and is a value weighted index which is based on the 500 American stocks with the largest market capitalizations. The S&P 500 is the most widely followed index After the Dow Jones Industrial Average index and it is considered a barometer for the American economy. The S&P 500 index is included in the Index of Leading Indicators. There are the number of trading vehicle that are designed to follow the S&P 500 index. Hundreds of billions of US dollars have been invested in this index. The SPY (Exchange Traded Fund) is one of the most actively trading stock over the world. The Rydex,[More...]

Forest Labs Hold Reiterated

Fri, 27 Mar 2009 19:01:00 GMT

Reiterating Hold Recommendation on Forest Labs Forest Laboratories, Inc. (FRX) turned in a very solid fiscal 2008. While 3rd quarter revenue was below our forecast, EPS was significantly better due to stronger operating margins as a result of better-than-expected gross margins and lower R&D and SG&A expenses. Revenue came in about $11 million shy of our expectations due to lower than forecast sales of Lexapro. We expect Lexapro sales to show a modest improvement now with the adolescent indication added to the label. Management's guidance for the full fiscal year remains below results in 2008, but has been revised upwards for[More...]

How To Spend $95 in Biotech

Wed, 18 Mar 2009 03:19:00 GMT

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors. We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech. Antisense Makes a Lot of Sense For a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense[More...]

Not Much Time to Save Earnings Season

Mon, 09 Feb 2009 17:21:00 GMT

Highlighted stocks include McKesson Corporation (MCK), Forest Laboratories (FRX), Exxon Mobil Corporation (XOM), Chevron Corporation (CVX) and ConocoPhillips (COP). Key Points: Earnings reports remain ugly, total net income[More...]

How Low Will they Go?

Mon, 02 Feb 2009 19:52:00 GMT

Highlighted stocks include Forest Labortatories, Inc. (FRX), McKesson Corporation (MCK), Monsanto Company (MON), Caterpillar, Inc. (CAT) and ConocoPhillips (COP). Key Points: Fourth-quarter reports remain ugly,[More...]

The Business Diary

Mon, 19 Oct 2009 05:50:00 GMT

Tomorrow the National Treasure Management Agency will embark on another fundraising mission with the aim of raising up to [euro]1 billion by auctioning Government bonds.
Results: Apple; Boston Scientific; First Derivatives; Hasbro.
Meeting: Barratt Developments egm; Redrow egm; Social Entrepreneurs Ireland awards presented by President Mary McAleese.

: iStockAnalyst.com Symbols Feed

Options Intelligence Report: High Energy Rewards For Option Trader At RRI

Forest's COPD Drug Disappoints

Spotlight On: Biotech

The Long And The Short Of It All: Fair Value By The Market

Analyst Blog: Forest Labs (NYSE: FRX) Pipeline Crucial

S&P 500 Stocks

Forest Labs Hold Reiterated

How To Spend $95 in Biotech

Not Much Time to Save Earnings Season

How Low Will they Go?

The Business Diary

IMS Health Cuts Pharma Growth Forecast

Business This Week - Apr 20 2009 1:57AM

Forest Laboratories Receives FDA Approval for Lexapro

Forest, Cypress Revise Timing for Commercial Availability of Savella

The Ticker - Feb 26 2009 8:51PM

Exxon Mobil Just May Be Mother of All Bellwethers

Movers: Corning, Ambac, Lehman, Coca-Cola, Staples, ConAgra

AstraZeneca: Third Quarter and Nine Months Results 2009

Pappas Ventures Names Eric Linsley Managing Partner

Forest Laboratories, Inc. And Nycomed Announce a Conference Call to Review Publication of Daxas® Phase III Clinical Trial Results

Nycomed and Forest Laboratories to Collaborate on Daxas® (roflumilast) for COPD

Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD

Biotech Hot in July Driven By Positive Drug Data and Acquisitions

Forest Laboratories, Inc. Reports Fiscal First Quarter 2010 Earnings Per Share of $0.87

Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 First Quarter Earnings

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization

Form 4 CANDEE WILLIAM J III For: Aug 10 (10K)

Form 4 GOODMAN KENNETH E For: Aug 10 (10K)

Form 4 GOLDWASSER DAN L For: Aug 10 (10K)

Form 4 COHAN GEORGE S For: Aug 10 (10K)

Form 4 Basgoz Nesli For: Aug 10 (10K)

Form 4 SALANS LESTER B For: Aug 10 (10K)

Form 4 SOLOMON HOWARD For: Jul 08 (10K)

Form 4 FOREST LABORATORIES INC For: Jun 16 Filed by: CANDEE WILLIAM J III (10K)

Form 4 COHAN GEORGE S For: Jun 10 (10K)

Form 4 OLANOFF LAWRENCE S For: Jun 08 (10K)